ASP4396 / Astellas - LARVOL DELTA

Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations. (ASCO 2025) - P1 | "Data will be summarized descriptively (mean, standard deviation, median) for continuous endpoints, and by counts and percentages for categorical endpoints. Study enrollment is ongoing."

Clinical • Metastases • P1 data • Oncology • Solid Tumor • Targeted Protein Degradation • KRAS

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=175 | Recruiting | Sponsor: Astellas Pharma Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor • KRAS

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=175 | Not yet recruiting | Sponsor: Astellas Pharma Inc

Metastases • New P1 trial • Oncology • Solid Tumor • KRAS